Soft Tissue Sarcoma

• FDA approval · 2025-09-04
  FDA Approved: PAZOPANIB — Original Application (Torrent Pharmaceuticals Limited)

  FDA approves Torrent Pharmaceuticals Limited's pazopanib hydrochloride as an original generic application (ANDA 219922).

• EMA approval · 2025-04-03
  EMA Authorised: Yondelis (trabectedin) — Pharma Mar S.A.

  EU marketing authorisation granted for Yondelis (trabectedin) for ovarian neoplasms and soft tissue sarcoma.

• CLINICAL_TRIALS approval · 2024-12-16
  Clinical Trial Update: Olaratumab (LY3012207) Patient Access for Soft Tissue Sarcoma

  Olaratumab has been approved for marketing for soft tissue sarcoma.

• FDA approval · 2024-12-04
  FDA Approved: PAZOPANIB — Original Application (Aurobindo Pharma Limited)

  FDA approved Aurobindo Pharma Limited's pazopanib ANDA 219034, a generic version of pazopanib. It is indicated for unresectable or metastati…

• FDA approval · 2024-11-08
  FDA Approved: PAZOPANIB — Supplemental Application (SUN PHARMACEUTICAL INDUSTRIES, INC.)

  FDA approved a supplemental application for pazopanib from Sun Pharmaceutical Industries, Inc. (ANDA 215837).

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• FDA approval · 2024-04-23
  FDA Approved: PAZOPANIB — Original Application (Novugen Pharma (USA) LLC.)

  FDA approved pazopanib hydrochloride as an original ANDA, enabling a generic version of pazopanib.

• FDA approval · 2023-10-19
  FDA Approved: PAZOPANIB — Original Application (Apotex Corp.)

  FDA approved an original Abbreviated New Drug Application for Pazopanib by Apotex Corp., providing a generic version of the cancer drug Pazo…

• FDA approval · 2023-10-19
  FDA Approved: PAZOPANIB — Original Application (Teva Pharmaceuticals, Inc.)

  FDA approval of a generic pazopanib product from Teva Pharmaceuticals under an Original Application (ANDA 217517).

• FDA approval · 2023-10-19
  FDA Approved: PAZOPANIB — Original Application (SUN PHARMACEUTICAL INDUSTRIES, INC.)

  FDA approved Sun Pharmaceutical's pazopanib as an original ANDA (generic) approval. The approval covers a generic version of pazopanib for t…

• FDA approval · 2021-12-13
  FDA Approved: VOTRIENT — Supplemental Application (Novartis Pharmaceuticals Corporation)

  FDA approved a supplemental application for VOTRIENT (pazopanib hydrochloride) from Novartis Pharmaceuticals Corporation. Pazopanib is used …

• FDA approval · 2020-08-17
  FDA Approved: VOTRIENT — Supplemental Application (Novartis Pharmaceuticals Corporation)

  FDA approved a supplemental application for VOTRIENT (pazopanib hydrochloride) by Novartis Pharmaceuticals Corporation. The approval updates…

• FDA approval · 2020-07-17
  FDA Approved: VOTRIENT — Supplemental Application (Novartis Pharmaceuticals Corporation)

  FDA approved a supplemental application for VOTRIENT (pazopanib hydrochloride) submitted by Novartis Pharmaceuticals Corporation.

• FDA approval · 2020-06-02
  FDA Approved: VOTRIENT — Supplemental Application (Novartis Pharmaceuticals Corporation)

  FDA approved a supplemental application for VOTRIENT (pazopanib hydrochloride) submitted by Novartis Pharmaceuticals Corporation.

• FDA approval · 2018-06-29
  FDA Approved: YONDELIS — Supplemental Application (Janssen Products, LP)

  FDA approved a supplemental application for YONDELIS (trabectedin) from Janssen Products, LP.

• FDA approval · 2017-11-03
  FDA Approved: DOXORUBICIN HYDROCHLORIDE — Supplemental Application (BluePoint Laboratories)

  FDA approved a supplemental application for doxorubicin hydrochloride from BluePoint Laboratories, adding a new approved generic version of …

• FDA approval · 2017-05-31
  FDA Approved: VOTRIENT — Supplemental Application (Novartis Pharmaceuticals Corporation)

  The FDA approved a supplemental application for VOTRIENT (pazopanib hydrochloride) submitted by Novartis Pharmaceuticals Corporation. The ap…

• EMA approval · 2016-09-16
  New treatment for patients with soft tissue sarcoma

  EMA announces a new treatment option for patients with soft tissue sarcoma, indicating authorization or positive assessment for a new therap…

• FDA approval · 2016-05-20
  FDA Approved: VOTRIENT — Supplemental Application (Novartis Pharmaceuticals Corporation)

  FDA approved a supplemental application for VOTRIENT (pazopanib hydrochloride) filed by Novartis Pharmaceuticals Corporation.

• FDA approval · 2015-10-23
  FDA Approved: YONDELIS — Original Application (Janssen Products, LP)

  FDA approved the original application for Yondelis (trabectedin) from Janssen, establishing its initial US indication for soft tissue sarcom…

• FDA approval · 2015-09-22
  FDA Approved: VOTRIENT — Supplemental Application (Novartis Pharmaceuticals Corporation)

  FDA approved a supplemental application for VOTRIENT (pazopanib hydrochloride) from Novartis Pharmaceuticals, signaling an update to the dru…

• FDA approval · 2014-11-18
  FDA Approved: VOTRIENT — Supplemental Application (Novartis Pharmaceuticals Corporation)

  The FDA approved a supplemental application for VOTRIENT (pazopanib hydrochloride) from Novartis Pharmaceuticals Corporation.

• FDA approval · 2014-11-05
  FDA Approved: DOXORUBICIN HYDROCHLORIDE — Supplemental Application (Fresenius Kabi USA, LLC)

  FDA approved a supplemental application for doxorubicin hydrochloride (Fresenius Kabi USA, LLC) under anANDA to support its generic product.

• FDA approval · 2013-11-27
  FDA Approved: VOTRIENT — Supplemental Application (Novartis Pharmaceuticals Corporation)

  FDA approved a supplemental application for VOTRIENT (pazopanib hydrochloride) submitted by Novartis Pharmaceuticals Corporation.

• FDA approval · 2013-02-04
  FDA Approved: DOXORUBICIN HYDROCHLORIDE — Original Application (BluePoint Laboratories)

  FDA approved a generic doxorubicin hydrochloride product under Original Application for BluePoint Laboratories (ANDA 203263). This marks app…

• FDA approval · 2012-04-26
  FDA Approved: VOTRIENT — Supplemental Application (Novartis Pharmaceuticals Corporation)

  The FDA approved a supplemental application for VOTRIENT (pazopanib hydrochloride) from Novartis Pharmaceuticals Corporation.